首页> 美国卫生研究院文献>other >Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin
【2h】

Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin

机译:多孔氧化硅-PLGA复合微球用于柔红霉素的持续眼部递送

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A water-soluble anthracycline antibiotic drug (daunorubicin, DNR) was loaded into oxidized porous silicon (pSiO2) microparticles and then encapsulated with a layer of polymer (poly lactide-co-glycolide, PLGA) to investigate their synergistic effects in control of DNR release. Similarly fabricated PLGA-DNR microspheres without pSiO2, and pSiO2 microparticles without PLGA were used as control particles. The composite microparticles synthesized by a solid-in-oil-in-water (S/O/W) emulsion method have mean diameters of 52.33±16.37 μm for PLGA-pSiO2_21/40-DNR and the mean diameter of 49.31±8.87 μm for PLGA-pSiO2_6/20-DNR. The mean size, 26.00±8 μm, of PLGA-DNR was significantly smaller, compared with the other two (p<0.0001). Optical microscopy revealed that PLGA-pSiO2-DNR microsphere contained multiple pSiO2 particles. In vitro release experiments determined that control PLGA-DNR microspheres completely released DNR within 38 days and control pSiO2-DNR microparticles (with no PLGA coating) released DNR within 14 days, while the PLGA-pSiO2-DNR microspheres released DNR for 74 days. Temporal release profiles of DNR from PLGA-pSiO2 composite particles indicated that both PLGA and pSiO2 contribute to the sustained release of the payload. The PLGA-pSiO2 composite displayed a more constant rate of DNR release than the pSiO2 control formulation, and it displayed a significantly slower release of DNR than either the PLGA or pSiO2 formulations. We conclude that this system may be useful in managing unwanted ocular proliferation when formulated with anti-proliferation compounds such as DNR.
机译:将水溶性蒽环类抗生素药物(柔红霉素,DNR)装入氧化的多孔硅(pSiO2)微粒中,然后用一层聚合物(聚丙交酯-乙交酯,PLGA)封装,以研究其在控制DNR释放中的协同作用。使用类似制备的不含pSiO2的PLGA-DNR微球和不含PLGA的pSiO2微粒作为对照颗粒。通过水包油(S / O / W)乳液法合成的复合微粒,PLGA-pSiO2_21 / 40-DNR的平均直径为52.33±16.37μm,PLGA-pSiO2_21 / 40-DNR的平均直径为49.31±8.87μm。 PLGA-pSiO2_6 / 20-DNR。与其他两个相比,PLGA-DNR的平均尺寸为26.00±8μm,明显较小(p <0.0001)。光学显微镜显示PLGA-pSiO2-DNR微球包含多个pSiO2颗粒。体外释放实验确定,对照PLGA-DNR微球在38天内完全释放DNR,而对照pSiO2-DNR微粒(无PLGA涂层)在14天内释放DNR,而PLGA-pSiO2-DNR微球在74天内释放DNR。从PLGA-pSiO2复合颗粒中DNR的时间释放曲线表明,PLGA和pSiO2均有助于有效负载的持续释放。 PLGA-pSiO2复合材料显示出比pSiO2对照配方更稳定的DNR释放速率,并且显示出比PLGA或pSiO2配方显着更慢的DNR释放速率。我们得出的结论是,与抗增殖化合物(如DNR)一起配制时,该系统可能对处理不必要的眼部增生有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号